Eli Lilly and Company
II - In-house lobbyists and trade/business/professional associations
Companies & groups
Lilly Corporate Centre, 1
Rue du Marquis 1
Mr John Lechleiter
Chairman and CEO
Mr Richard Ascroft
Senior Director Corporate Affairs and PRA
Lilly is a leading innovative biopharmaceutical company that unites caring with discovery to make life better for people around the world. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.
Headquartered in the US, Lilly has over 39.000 employees worldwide with approximately 9.000 based in Europe. In 2014 global revenue was approx. $19.5 billion, of which over 24% were invested in R&D.
Elanco is the animal health business unit of Lilly. Elanco is an innovation-based company which makes life sciences work better for people by transforming animal protein production and companion animal care. Elanco operates in 70 countries worldwide, focusing on products for companion animal and food animal health, vaccines, parasiticides, enzymes, diagnostics and aquaculture.
Both are part of Lilly as a single legal entity.
Human and animal healthcare legislation; Intellectual Property; European Medicines Agency; Clinical Trials Transparency; Health Technology Assessment; Transparency Directive; Falsified Medicines Directive; Trade; Industrial policy; Competition; Taxation; Environment; Innovative Medicines Initiative
Clinical Trials Directive, trade, intellectual property, EU 2020, Innovation Union, pharmaceuticals, healthcare, global health, innovation and research, veterinary medicine, business competitiveness, common agricultural policy, industrial policy.
50%: 3 25%: 1
Note: 3 colleagues are full-time engaged in the Brussels office and will spend approx 25% - 50% of their time on relevant EU affairs. A few other colleagues whereas spend a fraction of their time (0-5%).
|First name||Surname||Start Date||End Date|
Eli Lilly and Company is a member of the following associations and bodies: EFPIA, EuropaBio, AmChamEU, the British Chamber of Commerce to the EU, US Chamber of Commerce, Trans-Atlantic Business Council, American European Community Association, Trade Policy Network, EAASM, ASOP EU, IFAH-Europe, FEFAC.
01/2014 - 12/2014
700,000 € - 799,999 €
No funding received from the EU institutions during the last closed financial year.
This estimate is calculated according to pro rata staffing and office costs of Eli Lilly and Company staff involved in interest representation towards the European institutions as defined under the Register, based on the proportion of employee time devoted to these activities. In accordance with the Transparency Register Compliance guidelines on financial information, this estimate of costs as a range includes fees paid for outsourced activities (i.e consultancy contract fees). The estimate includes relevant membership fees to the various trade associations and other bodies. The list is included in the membership section of this form.
By its registration the organisation has signed the Transparency Register Code of Conduct.
The organisation has also declared to be bound to the following other Code:
EFPIA Codes - and the Eli Lilly Code of Conduct ("The Red Book-Code of Business Conduct")